ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
28 août 2023 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
14 août 2023 08h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
27 juin 2023 08h30 HE
|
ContraFect Corporation
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
19 déc. 2022 16h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
13 janv. 2020 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
18 déc. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 18, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
03 sept. 2019 07h00 HE
|
Allecra Therapeutics GmbH
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data
17 juin 2019 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
14 avr. 2019 07h42 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 ...
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
04 avr. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, New York, April 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...